Verrica Q4 2022 Earnings Report
Key Takeaways
Verrica Pharmaceuticals reported collaboration revenues of $0.1 million and a net loss of $5.9 million for the fourth quarter of 2022. The company's research and development expenses were $3.0 million, while general and administrative expenses totaled $3.2 million. As of December 31, 2022, Verrica had cash and cash equivalents of $34.3 million.
FDA accepted the filing of the resubmission of the NDA for VP-102 for the treatment of molluscum contagiosum.
VP-315 continues to advance, and the company remains on track to dose patients in Part 2 of its ongoing Phase 2 trial in the second quarter.
The company continues to make progress in its pre-commercial activities as it prepares for a potential U.S. launch of VP-102.
Raised gross proceeds of $32.5 million in secondary offering; pro forma cash and cash equivalents to fund planned operations into 1Q 2024.
Verrica
Verrica
Forward Guidance
Verrica believes it has sufficient cash and cash equivalents to support planned operations into the first quarter of 2024.